Compare Amphastar Pharmaceuticals Inc (AMPH) vs Rivian Automotive, Inc. (RIVN) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Rivian Automotive (RIVN) trades at $16.00, up 4.03% today, with a bullish technical signal and support at $15–16. The company reported Q2 2026 EPS of -$0.47, beating estimates, and raised 2026 delivery guidance to 65,000–70,000 vehicles. Revenue grew to $5.39B in 2025, but net losses persist at -$3.65B, with cash flow negative. Analyst consensus is mixed, with a $18.70 price target and 48% buy ratings.

Outlook hinges on R2 SUV ramp-up and cost controls, with potential for margin improvement by late 2026. Key risks include high cash burn, execution delays, and EV market competition. Upside exists if profitability targets are met, but investors face volatility amid funding needs and sector headwinds.